Drug Profile
Research programme: RNAi-based cystic fibrosis therapeutics - Alnylam/Cystic Fibrosis Foundation
Alternative Names: RNAi therapeutics - Alnylam/Cystic Fibrosis FoundationLatest Information Update: 04 May 2011
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; Cystic Fibrosis Foundation Therapeutics
- Developer Alnylam Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 05 Feb 2008 Preclinical development is ongoing
- 17 Mar 2005 Preclinical trials in Cystic fibrosis in USA (unspecified route)